Nano-Targeted Drug Delivery in Breast Cancer: Advances, Challenges and Clinical Perspective

Read full text Summarise with VIRAT
Authors: Anjali R. Alande, Shivappa N. Nagoba, Wasim Kazi, Bharti A.E, Rachita B. Malshette, Sanika Sonwane
Cited by: 0
References: 56

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Breast cancer remains the most frequently diagnosed malignancy among women worldwide and continues to be a leading cause of cancer-related mortality.Although conventional treatment strategies such as surgery, chemotherapy, radiotherapy, endocrine therapy, targeted therapy and immunotherapy have significantly improved patient outcomes, their clinical effectiveness is often limited by systemic toxicity, poor tumor selectivity, multidrug resistance, and unfavorable pharmacokinetic properties.These limitations emphasize the need for advanced drug delivery systems that can enhance therapeutic efficacy while minimizing adverse effects.In recent years, nanotechnology-based drug delivery systems have emerged as promising approaches for improving breast cancer treatment.Nanocarriers, generally ranging from 10 to 200 nm in size, possess unique physicochemical properties that enhance drug solubility, prolong systemic circulation and promote preferential accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect.In addition, surface modification and stimuli-responsive designs enable targeted and controlled drug release in response to tumor-associated conditions such as acidic pH, hypoxia, enzymatic activity and redox imbalance.Several nanomedicine formulations, including liposomal doxorubicin and albumin-bound paclitaxel, have already demonstrated clinical success in oncology.This review provides a comprehensive overview of different nanocarrier systems developed for breast cancer therapy, including liposomes, polymeric nanoparticles, dendrimers, polymeric micelles, solid lipid nanoparticles, nanostructured lipid carriers, metallic nanoparticles, mesoporous silica nanoparticles, carbon-based nanomaterials, quantum dots, exosomes and hybrid nanocarriers.Their structural features, preparation strategies, targeting mechanisms, advantages and limitations are discussed, along with current challenges in clinical translation.Overall, nanocarrier-based systems hold significant potential for advancing precision-based breast cancer therapy.

Fields of Study & Subjects

Nanoparticle-Based Drug Delivery Pharmacology and Nanomedicine Research Dendrimers and Hyperbranched Polymers

Publication details

Journal / source
International Journal of Pharmacy and Pharmaceutical Research
Volume
32
Issue
3
Pages
243–253
Publication date
1 January 2026
Language
EN